CIK 0001635077 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Aclarion, Inc.
Sign in to watch- Ticker
- ACON
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473324725
- Phone
- 833 275 2266
- Business address
- 8181 ARISTA PLACE, STE 100, BROOMFIELD, CO, 80021
- Former names
- Nocimed, Inc.
Securities
- ACON Common Stock Nasdaq
- ACONW Warrant Nasdaq
- 10-Q Report Quarterly Report
- 4 Open-market buy Director bought 5,857 shares at $2.73 ($15,990)
- 4 Open-market buy CFO bought 10,000 shares at $2.45 ($24,500)
- 4 Open-market buy Director bought 21,122 shares at $2.37 ($50,059)
- 4 Open-market buy Director bought 2,150 shares at $2.34 ($5,031)
- 4 Open-market buy Director bought 7,500 shares at $2.40 ($18,000)
- 4 Open-market buy Chief Executive Officer bought 5,234 shares at $2.31 ($12,091)
- 10-Q Report Quarterly Report
- S-8 Other Securities Offered to Employees in Benefit Plans
- 4 Grant or award Chief Strategy Officer acquired 55,000 shares (grant or award)
- 4 Grant or award Director acquired 20,000 shares (grant or award)
- 4 Grant or award Director acquired 20,000 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 50,000 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 100,000 shares (grant or award)
- 4 Grant or award Director acquired 20,000 shares (grant or award)
- 4 Grant or award Executive Chairman acquired 100,000 shares (grant or award)
- 4 Grant or award Director acquired 20,000 shares (grant or award)
- 4 Grant or award Director acquired 20,000 shares (grant or award)
- 8-K Event Shareholder vote results
- 10-Q Report Quarterly Report
Page 1 of 14 · 276 filings